Lupin Limited (Lupin) announces that it has achieved an S & P Global ESG Score of 91 for 2025, well above the pharmaceutical industry average of 28. Lupin is now part of an exclusive group of companies worldwide that have surpassed the 90-point mark.

This increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a player in sustainable growth.

Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin said, “Achieving a score above 90 in the S and P Global ESG ratings is rare global distinction, highlighting our unwavering commitment to sustainability. With a 15-point increase from last year, Lupin not only leads the pharmaceutical industry today, but redefines and sets new standards for responsible growth.

“Our

See Full Page